Cardiorenal outcomes of empagliflozin versus dapagliflozin in primary prevention among patients with type 2 diabetes: A nationwide cohort study
Main finding · Primary cardiorenal compositeResult — go to the resultHazard ratio 0.98 95% CI 0.89–1.09Authors' conclusion
This nationwide cohort study, empagliflozin and dapagliflozin showed similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without established cardiovascular or renal disease, supporting their clinical interchangeability for primary prevention in real-world practice.
Study context
- Population
- Patients with T2D newly initiating empagliflozin or dapagliflozin with no prior established cardiovascular or renal disease, Koreabefore PS matching
- Participants
- 135,559 patients
- Exposure
- Dapagliflozin vs empagliflozin
- Outcome
- First occurrence of cardiovascular death, MI, stroke, hospitalization for HF or progression to end-stage renal disease
Methodological details1:1 propensity score matched, Korean National Health Insurance Service database, new-user design
- 1:1 propensity score matched
- Korean National Health Insurance Service database
- New-user design
Main finding
Primary cardiorenal composite
Hazard ratio
0.98
95% CI 0.89–1.09
Dapagliflozinvs Empagliflozin
HR 0.98 (95% CI 0.89–1.09)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
MACE and individual components of the primary outcome
- Risks of secondary outcomes were comparable
Sensitivity analyses
- Overall findings consistent across several sensitivity analyses
Original publication
Cardiorenal outcomes of empagliflozin versus dapagliflozin in primary prevention among patients with type 2 diabetes: A nationwide cohort study. Diabetes Res Clin Pract. Published 2 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →